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GENES ENCODING SEVERAL POLY(ADP

metabolism, and thus PARP and PARG have been linked to

RIBOSE) GLYCOHYDROLASE (PARG)

the enhancement of DNA repair (4), limitation of malignant
transformation (5), enhancement of necrotic cell death (6),
and involvement in programmed cell death
To date,

ENZYMES, THE PROTEINS AND
FRAGMENTS THEREOF, AND ANTIBODIES

studies of the structure and function of the enZymes of

IMMUNOREACTIVE THEREWITH

ADP-ribose polymer metabolism have been mainly limited
CROSS REFERENCE TO RELATED
APPLICATION

to PARP
Little is knoWn about the function and regu
lation of PARG.

This application is a divisional of US. application Ser.

BRIEF SUMMARY OF THE INVENTION

No. 09/302,812 ?led Apr. 30, 1999, Which claims bene?ts of
1998. The entire disclosure of US. application Ser. No.

As embodied and broadly described herein, the present
invention is directed to nucleic acids molecules, peptides,

09/302,812 and US. Provisional Application No. 60/083,
768 is incorporated herein by reference.

poly(ADP-ribose) glycohydrolase (PARG) enZyme.

US. provisional Application No. 60/083,768 ?led May 1,

methods, vectors and antibodies that are related to the
15

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT

The present invention Was supported in part by the
National Institutes of Health (Grant CA43894). The United
States Government may have certain rights in the invention.

One embodiment of the invention is directed to an iso
lated and puri?ed nucleic acid molecule or nucleic acid
molecule analog comprising a sequence that encodes a

polypeptide having poly(ADP-ribose) glycohydrolase
20

(PARG) activity. The nucleic acid molecule may encode the
complete full-length PARG gene or a fragment of the PARG
gene. The nucleic acid molecule may be DNA, RNA or

peptide nucleic acid (PNA). The nucleic acid molecule can

TECHNICAL FIELD

be linear, such as, for eXample, an isolated fragment or a

The present invention relates to poly(ADP-ribose) glyco

hydrolases (PARGs) and peptides having poly(ADP-ribose)

25

linear phage DNA. In addition, the isolated nucleic acid
molecule may be circular, such as for eXample in a plasmid.

glycohydrolase activity. In addition, the invention also

The nucleic acid molecule may also be a single stranded

relates to antibodies, including monoclonal antibodies and

DNA or RNA such as the single stranded DNA or RNA in

antibody fragments, that have speci?c interaction With
epitopes present on poly(ADP-ribose) glycohydrolases.
Methods of treatment and diagnosis using the poly(ADP
ribose) glycohydrolases, and antibodies speci?c for poly
(ADP-ribose) glycohydrolases are disclosed. The present
invention has implications for the treatment of neoplastic

disorder, reperfusion folloWing ischemia, neurological
disorders, and related conditions.

30

35

BACKGROUND OF THE INVENTION

Genomic damage, if left unrepaired, can lead to malignant
transformation, or cell death by senescence (aging), necrosis

mammalian origin.
The nucleic acid molecule of the invention, may be of
mammalian origin, such as, for eXample of bovine or murine
origin. In a preferred embodiment of the invention, the
nucleic acid molecule may be of human origin. While the
sequence of the nucleic acid molecule is of mammalian
origin, the nucleic acid molecule may be replicated in
another organism such as an insert in a viral genome, a
plasmid in a bacterium or a 2-micron plasmid in a yeast.

40

or apoptosis. Among the variables that can affect the ulti
mate biological consequence of DNA damage to a particular
cell are
the amount, type, and location of the DNA

Preferably, the nucleic acid molecule has, a high degree of
sequence similarity With a sequence shoWn in SEQ ID NO:

damage and (ii) the ef?ciency and bioavailability of the
cellular DNA repair mechanism.

a single stranded DNA virus or single stranded RNA virus.
The nucleic acid molecule may be of yeast, insect or

45

1 (Genbank Accession Number U78975), SEQ ID NO:
(Genbank Accession Number AF005043), SEQ ID NO:
(Genbank Accession Number AF079557), SEQ ID NO:
(Genbank Accession Number AF079556) or SEQ ID NO:

3
5
7
9

The activation of poly(ADP-ribose) polymerase (PARP)

(Genbank Accession Number CEF20C5). The high degree

by DNA strand breaks is often one of the ?rst cellular

of sequence similarity may be, for example, about 70%,

responses to DNA damage. PARP catalyZes the conversion
of nicotinamide adenine dinucleotide (NAD) to multi
branched polymers containing up to 200 ADP-ribose resi
dues. Increases in polymer levels of more than 100-fold may
occur Within minutes of DNA damage. Once synthesiZed,
polymers are rapidly turned over, being converted to free

preferably about 80%, even more preferably about 90% and
most preferably substantially identical such as for eXample
50

ADP-ribose by the action of poly(ADP-ribose) glycohydro
lase (PARG)
An ADP-ribosyl protein lyase has been
proposed to catalyZe removal of protein-proximal ADP

55

ribose monomers

The nucleic acid molecule that encodes a polypeptide

having poly(ADP-ribose) glycohydrolase (PARG) activity
may be single or double stranded nucleic acid molecule of

FIG. 1 illustrates these processes

schematically.
The process of activating PARP upon DNA damage can
rapidly lead to energy depletion because each ADP-ribose

60

unit transferred by PARP consumes one molecule of NAD,

Which in turn, requires siX molecules of ATP to regenerate
NAD. Additionally, NAD is a key carrier of electrons needed
to generate ATP via electron transport and oXidative phos
phorylation or by glycolysis. The overactivation of PARP
due to substantial DNA damage can signi?cantly deplete the
cellular pools of NAD and ATP
ADP-ribose polymer

about 100% identity.

any length such as, for eXample, about 20 bases in length,
about 30 bases in length, about 40 bases in length, about 50
bases in length, about 100 bases in length, about 200 bases
in length, about 500 bases in length, about 1000 bases in
length, about 1500 bases in length, about 2000 bases in
length, about 3000 bases in length. It is understood that
“bases” in this patent application means “basepairs” When
referring to double stranded nucleic acid molecules and
bases When referring to single stranded nucleic acid mol
ecules. In a preferred embodiment of the invention, the
nucleic acid molecule may be at least about 1000 base or

65

basepairs long and have at least about 80% sequence simi
larity With a sequence shoWn in SEQ ID NO: 1, SEQ ID NO:
3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9.

